Effect of a phosphodiesterase 3 inhibitor, cilostazol, on bronchial hyperresponsiveness in elderly patients with asthma

International Archives of Allergy and Immunology

Volumn 114, Issue 4, 1997, Pages 379-384

  Fujimura, Masaki ^a   Kamio, Yumie ^b   Myou, Shigeharu ^a   Hashimoto, Takuma ^a   Matsuda, Tamotsu ^a  

^a KANAZAWA UNIV SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Asthma; Elderly patients; Hyperresponsiveness bronchial; Phosphodiesterase 3 inhibitor

Indexed keywords

CILOSTAZOL; METHACHOLINE; PHOSPHODIESTERASE INHIBITOR; THEOPHYLLINE;

ADULT; AGED; ARTICLE; ASTHMA; BRONCHODILATING ACTIVITY; BRONCHUS HYPERREACTIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; ELDERLY CARE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; VITAL CAPACITY;

EID: 0030781158     PISSN: 10182438     EISSN: 14230097     Source Type: Journal    
DOI: 10.1159/000237698     Document Type: Article

References (21)

1. Bcavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors, Trends Pharmacol Sci 1990;11:150-155.
2. Nicholson CD, Challis RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes, Trends Pharmacol Sci 1991:12:19-27.
3. Michaeli T, Bloom T, Martins T, Loughncy K, Ferguson K, Riggs M, Rodgers L, Beavo JA, Wigler M: Isolation and characterization of a previously undetected human cAMP phosphodiesterase by complementation of cAMP phosphodiesterase-deficient Saccharomyces cerevi-siae, J Biol Chem 1993:268:12925-12932.
4. Torphy TJ, Murray KJ, Arch JRS: Selective phosphodiesterase isozyme inhibitors; in Page CP, Metzger WJ (eds): Drugs and the Lung, New York, Raven Press, 1994, pp 397-447.
5. Dent G, Giembycz MA: Selective phosphodiesterase inhibitors in the therapy of asthma, Clin Immunother 1995:3:423-437.
6. Torphy TJ, Undcm BJ, Cieslenski LB, Lutt-mann MA, Reeves ML, Hay DWP: Identification, characterization and functional role of phosphodiesterase isozymes in human airway smooth muscle, J Pharmacol Exp Ther 1993; 265:1213-1223.
7. Howell RE, Sickcls BD, Wocppcl SL: Pulmonary antiallergic and bronchodilator effects of isozyme-sclcctive phosphodiesterase inhibitors in guinea pigs, J Pharmacol Exp Ther 1993:264: 609-615.
8. Boer J, Philpott AJ, Amsterdam GM, Shahid M, Zaagsma J, Nicholson CD: Human bronchial cyclic nucleotide phosphodiesterase isozymes: Biochemical and pharmacological analysis using selective inhibitors, Br J Pharmacol 1992; 106:1028-1034.
9. Foster RW, Rakshi K, Carpenter JR, Small RC: Trials of the bronchodilator activity of the isoenzymes-selective phosphodiesterase inhibitor AH 21-132 in healthy volunteers during a mcthacholine challenge test, Br J Clin Pharmacol 1992;34:527-534.
10. Fujimura M, Kamio Y, Saito M, Hashimoto T, Matsuda T: Bronchodilator and bronchoprotec-tive effects of cilostazol in humans in vivo, Am J Rcspir Crit Care Med 1995; 151:222-225.
11. Brunnee T, Engelstattcr R, Steinijans VW, Kunkel G: Bronchodilatory effect of inhaled zarda-verine, a phosphodiesterase III and IV inhibitor, in patients with asthma, Eur Rcspir J 1992;5: 982-985.
12. Ukcna D, Rentz K, Reiber C, Sybrccht GW: Effects of the mixed phosphodiesterase lll/IV inhibitor, zardaverine, on airway function in patients with chronic airflow obstruction, Rcspir Med 1995;89:441-444.
13. Tatii T, Sakurai K, Kimura Y, Ishikawa T, Hida-ka H: Pharmacological manipulation of tissue cyclic AMP by inhibitors: Effects of phosphodiesterase inhibitors on the functions of platelets and vascular endothelial cells, Adv Second Messenger Phosphoprotein Res 1992;25:215-227.
14. Mishima Y, Tanabe T, Sakaguchi S, Katsumura T, Kusaba A, Uchida H: Clinical efficacy of OPC-I30I3 for obstructive arteriosclerosis: A randomized, double-blinded study using ticlo-pidinc hydrochloride as an active placebo (in Japanese), Igakuno-ayumi 1986;139:133-157.
15. Lceman M, Lcjeune P, Melot C, Macije R: Reduction in pulmonary hypertension and in airway resistance by enoximonc (MDL 17,043) in decompensated COPD, Chest 1987;91:662-666.
16. Niki T, Mori H: Phase I study of cilostazol: Safety evaluation at increasing single doses in healthy volunteers, Arzneimittel forschung 1985;35:1173-1185.
17. Yasunaga K, Mase K: Antiaggregatory effect of oral cilostazol and recovery of platelet aggreg-ability in patients with cerebrovascular disease, Arneimittel forschung 1985;35:1189-1192.
18. Torphy TJ, Zhou HZ, Cieslinski LB: Stimulation of beta-adrenoccptors in a human monocyte cell line (U937) upregulates cyclic AMP-specific phosphodiesterase activity, J Pharmacol Exp Ther 1992;263:1195-1205.
19. Raz I, Bialer M, Salamc K, Baron II: Comparative pharmacokinetic analysis of a novel sus-taincd-rclcasc dosage form of theophylline in humans, Eur J Clin Pharmacol 1984:26:401-403.
20. Boushey HA, Holtzman MK, Sheller JR, Nadcl JA: Bronchial hyperreactivity, Am Rev Rcspir Dis 1980:121:384-413.
21. Cartier A, Lemire I, L’Archeveque J, Ghezzo H, Martin RR, Malo JL: Theophylline partially inhibits bronchoconstriction caused by inhaled histamine in subjects with asthma, J Allergy Clin Immunol 1986;77:570-575.